miRagen Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock

6 Feb 2020 - Yahoo News
BOULDER, Colo., Feb. 06, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it intends to offer for sale shares of its common stock and warrants to purchase shares ...
usx:mgen

---

miRagen Therapeutics Announces Positive Data for Cobomarsen in Adult T-Cell Leukemia/lymphoma Patients With Residual Disease

30 Jan 2020 - Yahoo News
BOULDER, Colo., Jan. 30, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced new efficacy and safety data from the ATLL arm of its ongoing Phase 1 clinical ...
usx:mgen

---

miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma at Two Upcoming Conferences

23 Jan 2020 - Yahoo News
BOULDER, Colo., Jan. 23, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced that it will present new efficacy and safety data from its Phase 1 trial ...
usx:mgen

---

miRagen Announces Major Changes to Company’s Strategy

11 Dec 2019 - Yahoo News
BOULDER, Colo., Dec. 11, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced a series of strategic changes across its business that are intended to reallocate ...
usx:mgen

---

miRagen to Present at the Evercore ISI HealthCONx Conference 2019

26 Nov 2019 - Yahoo News
BOULDER, Colo., Nov. 26, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced that management will be presenting at the Evercore ISI HealthCONx Conference ...
usx:mgen

---

Could Miragen Therapeutics, Inc.'s (NASDAQ:MGEN) Investor Composition Influence The Stock Price?

12 Nov 2019 - Yahoo News
A look at the shareholders of Miragen Therapeutics, Inc. (NASDAQ:MGEN) can tell us which group is most powerful...
usx:mgen

---

Signal Genetics, Inc. (MGEN) Reports Q3 Loss, Lags Revenue Estimates

7 Nov 2019 - Yahoo News
Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of -20.00% and -58.38%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
usx:mgen

---

miRagen Reports Third Quarter 2019 Results and Provides Corporate Update

7 Nov 2019 - Yahoo News
BOULDER, Colo., Nov. 07, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today reported financial results for the third quarter ended September 30, 2019 and provided ...
usx:mgen

---

Earnings Preview: Signal Genetics, Inc. (MGEN) Q3 Earnings Expected to Decline

31 Oct 2019 - Yahoo News
Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
usx:mgen

---

miRagen to Present at the DIA/FDA Oligonucleotide-Based Therapeutics Conference Today

28 Oct 2019 - Yahoo News
An overview of its second-generation miR-29 mimicsClinical development of its microRNA inhibitors BOULDER, Colo., Oct. 28, 2019 -- miRagen Therapeutics, Inc. (NASDAQ: MGEN),.
usx:mgen

---